Keyphrases
Cutaneous Adverse Drug Reactions (cADRs)
100%
Skin Reactions
66%
Immune Checkpoint Inhibitors
66%
Periorbital Edema
33%
Pityriasis Rubra pilaris
33%
Alpelisib
33%
Ipilimumab
25%
Checkpoint Inhibitors
23%
Cancer Treatment
18%
Dose Interruption
17%
Management Options
17%
Cutaneous Reaction
17%
Neutropenia
16%
Safety Patient
16%
Antiphospholipid Syndrome
16%
Healthy children
16%
Ecthyma Gangrenosum
16%
Combination Immunotherapy
16%
Incidence Management
16%
Interleukin-17 (IL-17)
16%
Ceramide
16%
Clinical Benefit
16%
Biologic Therapy
16%
Atopic Dermatitis
16%
Metastatic Melanoma
16%
Cancer Research
16%
Patient Consent
16%
Skin Barrier Repair
16%
Buschke-Löwenstein Tumor
16%
Paraneoplastic Pemphigus
16%
Neophallus
16%
Treatment Efficacy
16%
Immunosuppressed
16%
Medical Management
16%
Primary Hyperparathyroidism (pHPT)
16%
Single Institution Study
16%
Cutaneous Toxicity
16%
Hyaluronic Acid
16%
Management Benefits
16%
Surface Contour
16%
Anti-PD-1
16%
Erythrodermic
16%
Research Communication
16%
Anti-CTLA-4
16%
Osteonecrosis
16%
Multiple Myeloma
16%
Patient Acceptance
16%
Treatment Strategy
16%
Kaposi Sarcoma
16%
Keratosis pilaris Atrophicans
16%
Medicine and Dentistry
Adverse Event
69%
Pityriasis Rubra Pilaris
33%
Dermatological Agent
33%
Neoplasm
24%
Immunotherapy
22%
Immune-Related Adverse Events
21%
Bullous Pemphigoid
19%
Surgery
19%
Immune Checkpoint Inhibitor
18%
Acute Kidney Injury
16%
Biological Therapy
16%
Renal Artery
16%
Primary Hyperparathyroidism
16%
Beta Adrenergic Receptor Blocking Agent
16%
Accelerated Partial Breast Irradiation
16%
Kaposi Sarcoma
16%
Radiation Treatment Planning
16%
Giant Condyloma Acuminatum
16%
Retroperitoneal Sarcoma
16%
Paraneoplastic Pemphigus
16%
Metastatic Melanoma
16%
Gene Expression Profiling
16%
Immune Checkpoint Blockade
16%
Innate Immunity
16%
T Helper 1 Cell
16%
Toll Like Receptor 4
16%
Upregulation
16%
Capillary Hemangioma
16%
Alpelisib
16%
Brachytherapy
16%
Immunofluorescence
16%
Skin Toxicity
16%
Skin Manifestation
16%
Periorbital Edema
16%
Bone Necrosis
16%
Cancer Treatment
16%
Photosensitivity Disorder
16%
Multiple Myeloma
16%
Lichenoid
16%
Keratosis Pilaris Atrophicans
16%
Antiphospholipid Syndrome
16%
Paronychia
16%
Exanthem
16%
Phosphoinositide 3-Kinase Inhibitor
14%
Liposarcoma
12%
Ipilimumab
11%
Cytokine
11%
Systemic Lupus Erythematosus
11%
Skin Biopsy
11%
Human immunodeficiency virus
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
86%
Skin Manifestation
50%
Immune Checkpoint Inhibitor
50%
Ipilimumab
23%
Rash
19%
Atopic Dermatitis
16%
Ecthyma
16%
Hyaluronic Acid
16%
Beta Adrenergic Receptor Blocking Agent
16%
Capillary Hemangioma
16%
Periorbital Edema
16%
Tuberous Sclerosis
16%
Kaposi Sarcoma
16%
Ceramide
16%
Skin Toxicity
16%
Alpelisib
16%
Phosphatidylinositol 3 Kinase Inhibitor
14%
Clinical Trial
11%
HIV
11%
Hemangiofibroma
11%
Biological Product
9%
Neoplasm
9%
Pruritus
8%
Malignant Neoplasm
7%
Pathophysiology
6%
Rapamycin
5%
Combination Therapy
5%
Intellectual Impairment
5%
Monotherapy
5%
Autosomal Dominant Disorder
5%
Adenoma
5%
Interleukin 2
5%
Genetic Disorder
5%
Acne
5%
